CATHERINE OWEN is Senior Vice President (SVP) and General Manager, U.S. Commercialization. In this role, Owen has responsibility for Cardiovascular, Immunology and Oncology Commercialization at Bristol Myers Squibb. This organization contributed more than one-third of the company’s total revenue in 2021 exceeding $16B and consists of more than 2,500 employees who have delivered transformational medicines such as Eliquis, Opdivo, Yervoy, Zeposia, Opdualag, Camzyos and Orencia. She is a board member for the Pennsylvania Conference for Women, as well as on the Executive Committee of BIO(Biotechnology Innovation Organization), and an independent director on the board of Boston biotech company Agios Pharmaceuticals. Prior to her current role, Owen was SVP, Major Markets, where she was responsible for the BMS business in the largest global markets including Europe, Japan and Canada. Owen was responsible for ~$12BN (35%) of BMS total global sales, spanning therapeutic areas including Oncology, Hematology, CART, Cardiovascular, and Immunology, with many recognizable brands including Opdivo, Revlimid, Eliquis and Orencia. She had 8 company General Managers/Presidents reporting to her, responsible for over 6,000 employees. Owen led the complex integration of her BMS businesses with Celgene as well as multiple new product launches in multiple sclerosis, multiple myeloma, lung cancer, renal cancer and ulcerative colitis. Owen led the integration & transition during the global pandemic, responding rapidly to changes in the commercial operating model, commercialization, supply chain and legal entity rationalization. She championed the development of a new focus on global end of lifecycle management, including the creation of a new global franchise responsible for Established Brands. Previously, Owen was a senior executive at Johnson & Johnson (J&J). In her last role, she was President, Immunology, USA at Janssen Pharmaceuticals, responsible for leading the largest single business unit within J&J. The business included brands such as STELARA, REMICADE, SIMPONI and TREMFYA, leading over 1000 employees, and serving patients within the areas of dermatology, gastroenterology, and rheumatology. Previously, Owen was President, Infectious Diseases and Vaccines, where she led the U.S. commercial business in making a difference in the lives of people living with HIV, RSV and Ebola. Owen began her Johnson & Johnson career as a London-based sales representative. During her more than 25 years with J&J, she held leadership roles in Pharmaceuticals, Medical Devices and Corporate Innovation in the U.K., the U.S., Europe and global organizations. With a passion for digital connectivity, Owen established the first North America Pharmaceuticals Digital Governance Board and digital champions’ team at Janssen and served as Digital Governance Lead for North America. She also served as the first leader of the Janssen North America Culture Team, and in her role as Diversity & Inclusion lead for North America, Owen built the first Employee Resource Group Council. Owen is passionate about developing people, improving the lives of patients suffering from serious disease, and serves as a career mentor for many. In recognition of her efforts, she received the M&M Hall of Femme award in 2020, the Healthcare Businesswomen’s Association Luminary award in 2018 and represented J&J at Forbes ‘NexGen’ most powerful woman in Pharma. Owen has an Honors degree in Pharmacy from the University of Manchester and a post-graduate degree in Marketing from the University of London. She is a member of the Royal Pharmaceutical Society of Great Britain and is an Associate of the Chartered Institute of Marketing. She lives in Pennington, NJ with her husband and two teenage daughters.